21786300|t|Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy.
21786300|a|OBJECTIVE: Axonal degeneration is a main contributor to disability in progressive neurodegenerative diseases in which oxidative stress is often identified as a pathogenic factor. We aim to demonstrate that antioxidants are able to improve axonal degeneration and locomotor deficits in a mouse model of X-adrenoleukodystrophy (X-ALD). METHODS: X-ALD is a lethal disease caused by loss of function of the ABCD1 peroxisomal transporter of very long chain fatty acids (VLCFA). The mouse model for X-ALD exhibits a late onset neurological phenotype with locomotor disability and axonal degeneration in spinal cord resembling the most common phenotype of the disease, adrenomyeloneuropathy (X-AMN). Recently, we identified oxidative damage as an early event in life, and the excess of VLCFA as a generator of radical oxygen species (ROS) and oxidative damage to proteins in X-ALD. RESULTS: Here, we prove the capability of the antioxidants N-acetyl-cysteine, alpha-lipoic acid, and alpha-tocopherol to scavenge VLCFA-dependent ROS generation in vitro. Furthermore, in a preclinical setting, the cocktail of the 3 compounds reversed: (1) oxidative stress and lesions to proteins, (2) immunohistological signs of axonal degeneration, and (3) locomotor impairment in bar cross and treadmill tests. INTERPRETATION: We have established a direct link between oxidative stress and axonal damage in a mouse model of neurodegenerative disease. This conceptual proof of oxidative stress as a major disease-driving factor in X-AMN warrants translation into clinical trials for X-AMN, and invites assessment of antioxidant strategies in axonopathies in which oxidative damage might be a contributing factor.
21786300	18	37	axonal degeneration	Disease	MESH:D009410
21786300	43	48	mouse	Species	10090
21786300	58	80	X-adrenoleukodystrophy	Disease	MESH:D000326
21786300	93	112	Axonal degeneration	Disease	MESH:D009410
21786300	164	190	neurodegenerative diseases	Disease	MESH:D019636
21786300	321	340	axonal degeneration	Disease	MESH:D009410
21786300	345	363	locomotor deficits	Disease	MESH:D001523
21786300	369	374	mouse	Species	10090
21786300	384	406	X-adrenoleukodystrophy	Disease	MESH:D000326
21786300	408	413	X-ALD	Disease	MESH:D000326
21786300	425	430	X-ALD	Disease	MESH:D000326
21786300	485	490	ABCD1	Gene	11666
21786300	523	545	long chain fatty acids	Chemical	-
21786300	547	552	VLCFA	Chemical	MESH:C017364
21786300	559	564	mouse	Species	10090
21786300	575	580	X-ALD	Disease	MESH:D000326
21786300	631	651	locomotor disability	Disease	MESH:D009069
21786300	656	675	axonal degeneration	Disease	MESH:D009410
21786300	744	765	adrenomyeloneuropathy	Disease	MESH:D000326
21786300	767	772	X-AMN	Disease	MESH:D000326
21786300	861	866	VLCFA	Chemical	MESH:C017364
21786300	885	907	radical oxygen species	Chemical	-
21786300	909	912	ROS	Chemical	-
21786300	950	955	X-ALD	Disease	MESH:D000326
21786300	1016	1033	N-acetyl-cysteine	Chemical	MESH:D000111
21786300	1035	1052	alpha-lipoic acid	Chemical	MESH:D008063
21786300	1058	1074	alpha-tocopherol	Chemical	MESH:D024502
21786300	1087	1092	VLCFA	Chemical	MESH:C017364
21786300	1103	1106	ROS	Chemical	-
21786300	1287	1306	axonal degeneration	Disease	MESH:D009410
21786300	1316	1336	locomotor impairment	Disease	MESH:D001523
21786300	1450	1463	axonal damage	Disease	MESH:D001480
21786300	1469	1474	mouse	Species	10090
21786300	1484	1509	neurodegenerative disease	Disease	MESH:D019636
21786300	1590	1595	X-AMN	Disease	MESH:D000326
21786300	1642	1647	X-AMN	Disease	MESH:D000326
21786300	1701	1713	axonopathies	Disease	MESH:D016472
21786300	Negative_Correlation	MESH:D000111	MESH:D001523
21786300	Negative_Correlation	MESH:C017364	MESH:D008063
21786300	Negative_Correlation	MESH:C017364	MESH:D000111
21786300	Negative_Correlation	MESH:C017364	MESH:D024502
21786300	Negative_Correlation	MESH:D024502	MESH:D001523
21786300	Association	MESH:D000326	11666
21786300	Negative_Correlation	MESH:D008063	MESH:D001523
21786300	Negative_Correlation	MESH:D008063	MESH:D009410

